Predictive modeling for response to lithium and quetiapine in bipolar disorder

Bipolar Disorders

Volumn 21, Issue 5, 2019, Pages 428-436

  Kim, Thomas T ^a   Dufour, Steven ^b   Xu, Colin ^a   Cohen, Zachary D ^a   Sylvia, Louisa ^b,c   Deckersbach, Thilo ^b,c   DeRubeis, Robert J ^a   Nierenberg, Andrew A ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

bipolar disorder; lithium; machine learning; predictive modeling; quetiapine

Indexed keywords

LITHIUM; QUETIAPINE; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT;

AGORAPHOBIA; ARTICLE; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DSM-IV-TR; ELASTIC NET REGULARIZATION; EMPLOYMENT; HUMAN; MAJOR CLINICAL STUDY; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SOCIAL PHOBIA; THEORETICAL MODEL; TREATMENT RESPONSE; ADULT; BIOLOGICAL MODEL; BIPOLAR DISORDER; COMPLICATION; FEMALE; MACHINE LEARNING; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIPOLAR DISORDER; COMORBIDITY; FEMALE; HUMANS; LITHIUM COMPOUNDS; MACHINE LEARNING; MALE; MODELS, BIOLOGICAL; PRECISION MEDICINE; QUETIAPINE FUMARATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85062330846     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12752     Document Type: Article

References (54)

1. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. The Lancet. 2013;381(9878):1672-1682.
2. Baca-Garcia E, Gronzalez de Rivera JL, Saiz-Ruiz J, et al. Diagnostic stability and evolution of bipolar disorder in clinical practice: a prospective cohort study. Acta Psychiatr Scand. 2007;115:473-480.
3. Treuer T, Tohen M. Predicting the course and outcome of bipolar disorder: a review. Eur Psychiatry. 2010;25(6):328-333.
4. Connolly KR, Thase ME. The clinical management of bipolar disorder: a review of evidence-based guidelines. Prim Care Companion CNS Disord. 2011;13(4).
5. Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry. 2016;15(1):53-58.
6. Nierenberg AA, McElroy SL, Friedman ES, et al. Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. J Clin Psychiatry. 2016;77(1):90-99.
7. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66(1):111-121.
8. Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71(2):150-162.
9. Kleindienst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord. 2005;7(5):404-417.
10. Grof P. Sixty years of lithium responders. Neuropsychobiology. 2010;62(1):8-16.
11. Backlund L, Ehnvall A, Hetta J, Isacsson G, Ågren H. Identifying predictors for good lithium response–a retrospective analysis of 100 patients with bipolar disorder using a life-charting method. Eur Psychiatry. 2009;24(3):171-177.
12. Tighe SK, Mahon PB, Potash JB. Predictors of lithium response in bipolar disorder. Ther Adv Chronic Dis. 2011;2(3):209-226.
13. Hou L, Heilbronner U, Degenhardt F, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016;387(10023):1085-1093.
14. Chekroud AM, Zotti RJ, Shehzad Z, et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry. 2016;3(3):243-250.
15. Ludlow L, Klein K. Suppressor variables: the difference between ‘is’ versus ‘acting as’. J Stat Educ. 2014;22(2): 1-28.
16. Vieta E, Parramon G, Padrell E, et al. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord. 2002;4(5):335-340.
17. Cohen ZD, Kim TT, Van HL, Dekker J, Driessen E. A demonstration of a multi-method variable selection approach for treatment selection: Recommending cognitive–behavioral versus psychodynamic therapy for mild to moderate adult depression. Psychother Res. 2019;1-14. https://doi.org/10.1080/10503307.2018.1563312.
18. Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc Series B Stat Methodol. 2005;67(2):301-320.
19. Webb CA, Trivedi MH, Cohen ZD, et al. Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study. Psychol Med. 2018;1-10.
20. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66(7):870-886.
21. Nierenberg AA, Sylvia LG, Leon AC, et al. Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder. Clin Trials. 2014;11(1):114-127.
22. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159-171.
23. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326.
24. Trivedi MH, Wisniewski SR, Morris DW, et al. Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry. 2011;72(6):757.
25. Leon AC, Solomon DA, Mueller TI, et al. A brief assessment of psychosocial functioning of subjects with bipolar I disorder: the LIFE-RIFT. J Nerv Ment Dis. 2000;188(12):805-812.
26. Gonzalez JM, Bowden CL, Katz MM, et al. Development of the Bipolar Inventory of Symptoms Scale: concurrent validity, discriminant validity and retest reliability. International journal of methods in psychiatric research. 2008;17(4):198-209.
27. Kuhn M, Johnson K. Applied predictive modeling, Vol. 26. New York, NY:Springer; 2013.
28. Stekhoven DJ, Buhlmann P. MissForest–non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012;28(1):112-118.
29. Kuhn M, Johnson K. Applied predictive modeling. New York, NY:Springer Science & Business Media; 2013.
30. Williams CK, Engelhardt A, Cooper T, et al. Package ‘caret’. 2018. https://cran.r-project.org/web/packages/caret/caret.pdf. Accessed August 20, 2018.
31. Kraemer HC, Blasey CM. Centring in regression analyses: a strategy to prevent errors in statistical inference. Int J Methods Psychiatr Res. 2004;13(3):141-151.
32. Friedman J, Hastie T, TibshiraniR. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1-22.
33. TibshiraniRJ. Regression shrinkage and selection via the. J R Stat Soc Series B Stat Methodol. 1996;267-288.
34. Piñeiro G, Perelman S, Guerschman JP, Paruelo JM. How to evaluate models: observed vs. predicted or predicted vs. observed? Ecol Modell. 2008;216(3–4):316-322.
35. Smith EP, RoseKA. Model goodness-of-fit analysis using regression and related techniques. Ecol Modell. 1995;77(1):49-64.
36. Cohen J. Statistical power analysis for the behavioral sciences (2nd ed). In Hillsdale NJ. L. Erlbaum Associates; 1988.
37. Cohen J. A power primer. Psychol Bull. 1992;112(1):155-159.
38. Karaahmet E, Konuk N, Dalkilic A, et al. The comorbidity of adult attention-deficit/hyperactivity disorder in bipolar disorder patients. Compr Psychiatry. 2013;54(5):549-555.
39. Nierenberg AA, Miyahara S, Spencer T, et al. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiat. 2005;57(11):1467-1473.
40. Tamam L, Karakus G, Ozpoyraz N. Comorbidity of adult attention-deficit hyperactivity disorder and bipolar disorder: prevalence and clinical correlates. Eur Arch Psychiatry Clin Neurosci. 2008;258(7):385-393.
41. Perroud N, Cordera P, Zimmermann J, et al. Comorbidity between attention deficit hyperactivity disorder (ADHD) and bipolar disorder in a specialized mood disorders outpatient clinic. J Affect Disord. 2014;168:161-166.
42. Young LT, Cooke RG, Robb JC, Levitt AJ, Joffe RT. Anxious and non-anxious bipolar disorder. J Affect Disord. 1993;29:49-52.
43. Bobo WV, Reilly-Harrington NA, Ketter TA, et al. Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial. J Affect Disord. 2014;161:30-35.
44. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry. 1986;143:29-34.
45. Jann MW. Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments. Am Health Drug Benefits. 2014;7(9):489.
46. Hayes JF, Pitman A, Marston L, et al. Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: A UK Population-Based Electronic Health Records Study. JAMA Psychiatry. 2016;73(6):630-637.
47. Vitiello B, Riddle MA, Yenokyan G, et al. Treatment moderators and predictors of outcome in the Treatment of Early Age Mania (TEAM) study. J Am Acad Child Adolesc Psychiatry. 2012;51(9):867-878.
48. Swann AC, Bowden CL, Morris D, et al. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry. 1997;54(1):37-42.
49. Strakowski SM, DelBello MP, Fleck DE, Arndt S. The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry. 2000;48(6):477-485.
50. Brown ES, Nejtek VA, Perantie DC, Bobadilla L. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord. 2002;4(6):406-411.
51. DeRubeis RJ, Cohen ZD, Forand NR, Fournier JC, Gelfand LA, Lorenzo-Luaces L. The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration. PLoS ONE. 2014;9(1):e83875.
52. Kessler RC. The potential of predictive analytics to provide clinical decision support in depression treatment planning. Curr Opin Psychiatry. 2018;31(1):32-39.
53. Wrathall J, Belnap T. Reducing health care costs through patient targeting: risk adjustment modeling to predict patients remaining high cost. EGEMS (Wash DC). 2017;5(2):4.
54. Cohen ZD, DeRubeis RJ. Treatment selection in depression. Annu Rev Clin Psychol. 2018;14.